As compared with the established tumor markers, Tumor M2-PK in EDTA-plasma proves to have at least equal sensitivity in pancreatic, gastric, esophageal, colorectal and cholangiocellular cancer.

There is no one test, either blood test or x-ray, that can be ordered to see if pancreatic cancer is present. A series of tests are done, and they may include: a complete metabolic panel, liver panel, ...

The same mRNA technology behind COVID-19 vaccines is now being used in the fight against cancer, and the University of ...

The UK-based Medical Detection Dogs Charity has started a groundbreaking 2025 study, training dogs to sniff out early-stage ...

T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor ...

“This is quite preliminary in discovery, in terms of can we identify a marker in an extracellular vesicle that may indicate the onset of pancreatic cancer,” said Greening. However, because there are ...

As with MCN, patients with borderline tumors or carcinoma in situ are usually cured. With invasive carcinoma, the 5 and 10-year survival is 60% and 50% which is much better than typical pancreatic ...

The latest grant is intended to support the company’s Phase 1 PANACEA study evaluating the safety and tolerability of MT-601 in patients with metastatic pancreatic cancer. Marker Therapeutics ...

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective treatment options for the disease. In a new study, researchers at ...